Abstract 1130: First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER+ breast cancer with KAT6A dysregulation
Shikhar Sharma(Pfizer (United States)), Thomas A. Paul(Pfizer (United States)), Yong Zhang(Shanghai East Hospital), Amanda J. Rickard(Monash Institute of Medical Research), Soroor Hediyeh-zadeh(Helmholtz Zentrum München), Yuqing Yang(The University of Melbourne), Jane E. Visvader(Walter and Eliza Hall Institute of Medical Research), Brendon J. Monahan(Monash University), Thomas S. Peat(UNSW Sydney), Melissa J. Davis(The University of Queensland), Michelle A. Camerino(Monash University), Jay H. Chung(National Heart Lung and Blood Institute), Catalina Carrasco‐Pozo(University of Talca), Ian P. Street(Unknown), Patrick Bingham(Pfizer (United States)), James R. Whittle(Walter and Eliza Hall Institute of Medical Research), Showkhin Khan(Pfizer (United States)), Pei‐Pei Kung(Pfizer (United States)), Bin Ren(Commonwealth Scientific and Industrial Research Organisation), Anne K. Voss(Walter and Eliza Hall Institute of Medical Research), Melanie de Silva, Natalie Nady(Pfizer (United States)), Karen L. White(Monash University), Mark A. Dawson(The University of Melbourne), Vicky M. Avery(Griffith University), Stewart D. Nuttall(Commonwealth Scientific and Industrial Research Organisation), Ylva E. Bozikis(Monash University), Elizabeth Allan(The University of Melbourne), Rachel Lagiakos(Commonwealth Scientific and Industrial Research Organisation), Olan Dolezal(Commonwealth Scientific and Industrial Research Organisation), Susan A. Charman(Monash University), Paul A. Stupple(Monash University), Karen A. Maegley(Pfizer (United States)), Elliot Surgenor(Walter and Eliza Hall Institute of Medical Research), Hendrik Falk(Commonwealth Scientific and Industrial Research Organisation), Tim Thomas(The University of Melbourne), Miriam Butler(Cooper Medical School of Rowan University), Geoffrey J. Lindeman(The University of Melbourne), Sean Uryu(Pfizer (United States)), Chin Wee Tan(The University of Queensland), Alexandra E. Stupple(Monash University), Matthew L. Dennis(Commonwealth Scientific and Industrial Research Organisation), Haikuo Zhang(Brigham and Women's Hospital), Zhenxiong Wang(Pfizer (United States)), Dawson Sarah-Jane(Peter MacCallum Cancer Centre), Eric Greenwald(Pfizer (United States)), Laura MacPherson(Natural Resources Canada), Hieu Lam(Pfizer (United States)), François Vaillant(The University of Melbourne)
Cited by 14
Related Papers
Model-based Analysis of ChIP-Seq (MACS)
|Genome biology|2008|20k
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Identifying ChIP-seq enrichment using MACS
|Nature Protocols|2012|2.1k
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
|Nature|2011|1.5k
Best practices for single-cell analysis across modalities
|Nature Reviews Genetics|2023|1k